Navigation Links
Aethlon Medical to Present at Rodman & Renshaw Annual Global Investment Conference
Date:8/30/2010

ism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.

Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs.  However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union.  In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.

As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:

  1. Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
  2. Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.  
  3. Human Immunodeficiency Virus (HIV):  Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to a
    '/>"/>

SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009
2. Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
3. Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus
4. Aethlon Medical Discloses Live Webcast of Todays BIOCOM Presentation
5. Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs
6. Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. Globus Medical Raises $110 Million in Series E Financing Round
11. Quark Pharmaceuticals Appoints New Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015  Lyric Pharmaceuticals Inc. today ... round totaling $20.4 million. The financing, co-led by RiverVest ... participation by Aperture Venture Partners. Lyric ... David Wurtman , M.D., M.B.A., President & Chief ... Chief Medical Officer.  In 2014, Lyric closed a seed ...
(Date:2/26/2015)... People with psoriasis and their health ... in research that aims to improve treatments and ... registry begins recruiting patients in 2015. ... Psoriasis Foundation and Corrona, LLC, will initially track ... biologic medication by Novartis Pharmaceuticals for moderate-to-severe psoriasis. ...
(Date:2/26/2015)... , February 26, 2015 ... please scroll to bottom . Investor-Edge has ... (NYSE: JNJ ), Teva Pharmaceutical Industries Ltd ... ENDP ), Allergan Inc. (NYSE: ... ). Free research report on Johnson and Johnson can ...
Breaking Medicine Technology:First independent U.S. psoriasis registry will track drug safety and effectiveness 2First independent U.S. psoriasis registry will track drug safety and effectiveness 3Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 2Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 3Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 4Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 5
... 1 BioMarin Pharmaceutical Inc. (Nasdaq: ... studies on Kuvan (sapropterin dihydrochloride) are being presented ... for The Study of Inborn Errors of Metabolism ... reported that PKU patients taking Kuvan showed improvements ...
... study conducted by oculoplastic surgeon Charles Soparkar, M.D., ... patent-pending formulation of zinc and phytase (trademarked as ... administration for 4 days prior to a planned ... in 41 of 44 patients tested (93%).  Phytase ...
Cached Medicine Technology:Results From Investigator-Sponsored Trials Presented at SSIEM Conference 2Results From Investigator-Sponsored Trials Presented at SSIEM Conference 3Results From Investigator-Sponsored Trials Presented at SSIEM Conference 4Proprietary Zinc/Phytase Formulation Improved Botulinum Toxin A Results 2
(Date:2/27/2015)... 27, 2015 Plugin creators from Pixel Film ... Final Cut Pro X. , “TransFold Volume 3 gives users ... FCPX users.” Said Christina Austin, CEO of Pixel Film ... Cut Pro X editor.” , TransFold Volume 3 comes packed ... The user can decide to change the shadow distance, opacity, ...
(Date:2/26/2015)... (PRWEB) February 27, 2015 2015 Deep ... a professional and in-depth study on the current state ... a focus on the Chinese situation. , Major companies ... SHANGDONG ZOUPING, Hualun, Jiangsu Yuanyang, ZHENGZHOU TONGLI, Hebei ... and Jain & Jain. , The report provides a ...
(Date:2/26/2015)... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... says contains absolute proof that the bible can be trusted ... the plan, or purpose for mankind is. He says a ... beginning and an end. , “Yahweh has allotted 6,000 ... walk in His Righteousness, and who will not. Those who ...
(Date:2/26/2015)... Marking its fifth successful year of business, UV ... the development of a new and improved UV-Aid light supplement ... spring. UV-Aid is a unique and patent pending technology that ... areas of the body susceptible to infection. UVA light has ... daily dose of UV-Aid is equivalent to less than a ...
(Date:2/26/2015)... 2015 Healthpointe is proud to ... Dr. Neil Thomas Katz, MD, is now offering ... throughout Southern California, including Long Beach , ... and fellowship-trained to provide quality care, and specializes ... Neil Katz provides surgical and non-surgical treatments for ...
Breaking Medicine News(10 mins):Health News:Announcing a New TransFold Transition Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:World Benzoyl Peroxide Market Forecast Report 2015-2020 Now at Available DeepResearchReports.com 2Health News:World Benzoyl Peroxide Market Forecast Report 2015-2020 Now at Available DeepResearchReports.com 3Health News:Yisrayl Hawkins Says There is Only One Place Shown in Scripture to Achieve Salvation and Shows Proof in New Letter 2Health News:UV Technologies, LLC Developing New More Effective UV-Aid for Flu and Cold Prevention 2Health News:Southern California Medical Group is Now Offering Orthopedic Care for Cartilage Injuries and Degeneration 2Health News:Southern California Medical Group is Now Offering Orthopedic Care for Cartilage Injuries and Degeneration 3
... found that Salmonella bacteria found in garden birds are ... the bacteria found in livestock and humans. , Salmonella ... undetected in animals, which increases the risk of the ... strains found in birds in the laboratory and found ...
... of NSCLC, CHICAGO, June 2 Exelixis, Inc. ... of XL647, a novel small molecule,inhibitor of EGFR, HER2, ... Society of Clinical Oncology (ASCO). Updated data from an ... cell,lung cancer (NSCLC) patients show encouraging anti-tumor activity of ...
... NEW YORK, June 2 American Oriental,Bioengineering (NYSE: ... of Directors has,authorized a share repurchase program for ... Company,s outstanding common stock., Purchases under this ... in the,open market, privately negotiated transactions, and accelerated ...
... Pain Patients with Substance ... Use Disorders WHO: ... 4th - 6th, ... pm, PHILADELPHIA, June 2 Valley Forge Medical Center and,Hospital is the first facility on ...
... with a combination of chemotherapy, biotherapy and radiotherapy prior ... patients, according to a University of Pittsburgh Cancer Institute ... the American Society of Clinical Oncology (ASCO) in Chicago. ... Cancer Center of the University of Pittsburgh Medical Center ...
... CO June 2, 2008 Results from an ... and lost time among employees suffering from multiple sclerosis ... were presented and announced by Biogen Idec as poster ... annual meeting in Denver, Colorado, May 28-May 31, 2008. ...
Cached Medicine News:Health News:Salmonella in garden birds responsive to antibiotics 2Health News:Exelixis Reports Phase 1 and Phase 2 Data For XL647 at ASCO 2Health News:Exelixis Reports Phase 1 and Phase 2 Data For XL647 at ASCO 3Health News:Exelixis Reports Phase 1 and Phase 2 Data For XL647 at ASCO 4Health News:Exelixis Reports Phase 1 and Phase 2 Data For XL647 at ASCO 5Health News:Exelixis Reports Phase 1 and Phase 2 Data For XL647 at ASCO 6Health News:American Oriental Bioengineering Announces US$75 Million Share Repurchase Program 2Health News:Valley Forge Medical Center and Hospital to Become the First Addiction-Free Pain Management Center of Excellence on the East Coast; Will Host Three Day Professional Training Seminar. 2Health News:Valley Forge Medical Center and Hospital to Become the First Addiction-Free Pain Management Center of Excellence on the East Coast; Will Host Three Day Professional Training Seminar. 3Health News:New treatment combination safe for pancreatic cancer patients 2Health News:New data show patients using avonex reported less sick leave and short-term disability costs 2
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: